Maravai LifeSciences shares rise 18% in debut [Reuters]
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Reuters
Maravai LifeSciences shares rise 18% in debut By Reuters Staff 1 Min Read Nov 20 (Reuters) - Shares of Maravai LifeSciences, which provides a capping reagent to Pfizer and BioNTech for their COVID-19 vaccine, rose 18.3% in their debut on Friday, after the company raised $1.62 billion in its upsized initial public offering. (Reporting by Noor Zainab Hussain in Bengaluru; Editing by Maju Samuel)
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production [Yahoo! Finance]Yahoo! Finance
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionBusiness Wire
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024GlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Should You Sell Maravai LifeSciences (MRVI)? [Yahoo! Finance]Yahoo! Finance
MRVI
Earnings
- 2/22/24 - Beat
MRVI
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/16/24 - Form 4
- MRVI's page on the SEC website